Redeye initiates coverage of Scandinavian ChemoTech, a Swedish medtech company in early-stage commercialisation with its tumour-specific electroporation (TSE) treatment method for both humans and animal cancer patients. Scandinavian ChemoTech awaits case study data from superficial and deep-seated tumours, and we believe its technology has the potential to disrupt the cancer market.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/